Big DNA gains new backing to advance vax tech

An international consortium has invested £1.5 million in Scotland's Big DNA. The money is being used to advance the biotech company's technology using bacterial viruses to deliver vaccines. These bacteriophages include the genetic code, or DNA, rather than the disease organism.

"In the current financial climate, this investment confirms the strength of our new technology for delivering vaccines to humans and animals, the vast potential of the market and the strength of the management team we are putting in place," said founder and CEO Dr John March. "Our patented technology has enormous potential importance for public health and this investment comes at a time when it must be the hardest in living memory to raise finance."

Clinical trials of the DNA vaccine are expected in about two years.

- check out the report from The Scotsman

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.